<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24245774</article-id>
      <article-id pub-id-type="pmc">3843542</article-id>
      <article-id pub-id-type="publisher-id">1756-0500-6-471</article-id>
      <article-id pub-id-type="doi">10.1186/1756-0500-6-471</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Sibertin-Blanc</surname>
            <given-names>Camille</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>camillesibertin@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Norguet</surname>
            <given-names>Emmanuelle</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>emmanuelle.norguet@ap-hm.fr</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Duluc</surname>
            <given-names>Muriel</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>muriel.duluc@ap-hm.fr</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Louis</surname>
            <given-names>Guillaume</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>guillaume.louis@ap-hm.fr</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Seitz</surname>
            <given-names>Jean-Fran&#xE7;ois</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>jseitz@ap-hm.fr</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A6">
          <name>
            <surname>Dahan</surname>
            <given-names>Laetitia</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>laetitia.dahan@mail.ap-hm.fr</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Assistance Publique &#x2013; H&#xF4;pitaux de Marseille, Service d&#x2019;oncologie digestive, H&#xF4;pital Timone, Universit&#xE9; de la M&#xE9;diterran&#xE9;e, Marseille, France</aff>
      <aff id="I2"><label>2</label>Assistance Publique &#x2013; H&#xF4;pitaux de Marseille, Service de radiologie, H&#xF4;pital Timone, Universit&#xE9; de la M&#xE9;diterran&#xE9;e, Marseille, France</aff>
      <aff id="I3"><label>3</label>CHU Timone, 264 rue Saint Pierre, F-13385 Marseille cedex 5, France</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>11</month>
        <year>2013</year>
      </pub-date>
      <volume>6</volume>
      <fpage>471</fpage>
      <lpage>471</lpage>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>7</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>11</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Sibertin-Blanc et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Sibertin-Blanc et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1756-0500/6/471"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We report here on the case of a patient presenting with hypersensitivity pneumonitis while being treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>Side effects of everolimus should be familiar to clinicians, including nonspecialists, and be monitored carefully to allow for prompt management.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>Neuroendocrine tumor</kwd>
        <kwd>Everolimus</kwd>
        <kwd>Hypersensitivity pneumonitis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>The incidence of neuroendocrine tumours is increasing. They are often diagnosed at an advanced stage, with conventional chemotherapy treatments having a limited effect. Therefore, novel therapeutic agents are currently being investigated, notably everolimus, a mammalian target of rapamycin (mTOR) inhibitor.</p>
      <p>Neuroendocrine tumours have recently been shown to display a genetic anomaly that may lead to an activation of the mTOR pathway [<xref ref-type="bibr" rid="B1">1</xref>]. The mTOR kinase protein, however, is a central regulator of cellular proliferation, growth, angiogenesis, and metabolism [<xref ref-type="bibr" rid="B2">2</xref>]. The predominant side effects of everolimus therapy include mucositis and buccal ulcers, but less commonly, hypersensitivity pneumonitis. We report here on the case of a patient presenting with hypersensitivity pneumonitis while being treated with everolimus.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 52-year-old man was followed up in our centre for a small intestinal neuroendocrine tumour with hepatic synchronous metastases diagnosed in 2001. The patient initially underwent small bowel and hepatic surgery combined with radiofrequency ablation, the latter being repeated in 2005 for a recurrence of hepatic metastases. Due to the progression of the disease, the patient was included in the Radiant-2 [<xref ref-type="bibr" rid="B3">3</xref>] trial that evaluated the efficacy of octreotide plus everolimus versus placebo plus octreotide on progression-free survival (PFS); he remained in the study for a period of 2&#xA0;years. Following the initial stabilisation of the hepatic lesions, the patient experienced disease progression, leading to withdrawal from the study. Unblinding revealed that the patient was in the placebo plus octreotide arm.</p>
      <p>In February 2010, everolimus therapy was initiated. Three months later, the first evaluation revealed a partial response, with a decrease in tumour size by 28% according to RECIST (Response Evaluation Criteria In Solid Tumours) criteria. During the 4th month of treatment, the patient experienced disabling dyspnoea of grade 2, without cough. Blood gas analysis showed uncompensated respiratory alkalosis. On thoracic computed-tomography (CT) scan, there was a pattern of alveolar condensation and air bronchogram in the left and right inferior lobes (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>). Pulmonary function testing revealed a moderate restrictive syndrome. The bronchoalveolar lavage (BAL) showed lymphocyte-predominant alveolitis, while bacterial screening and serology tests of atypical pneumonia were negative. It was assumed that the patient&#x2019;s symptoms were due to Grade 3 hypersensitivity pneumonitis, which was likely linked to everolimus therapy. Consequently, the treatment was interrupted, following which the patient&#x2019;s respiratory symptoms returned to normal as did CT images (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Scan taken at 4&#xA0;months following the initiation of everolimus therapy during the dyspnoea episode: alveolar condensation of the right and left inferior lobe with an air bronchogram, predominant on the left-side.</p>
        </caption>
        <graphic xlink:href="1756-0500-6-471-1"/>
      </fig>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Control scan at 4&#xA0;months after everolimus discontinuation: regression of bilateral parenchymatous lesions.</p>
        </caption>
        <graphic xlink:href="1756-0500-6-471-2"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Everolimus is currently used in the treatment of a number of diseases: metastatic renal cancer resistant to sorafenib or sunitinib, non-small cell lung cancer unresponsive to anti-epidermal growth factor receptor (EGFR) therapy, as well as in cardiac or renal transplant patients. In addition, the drug is undergoing evaluation in metastatic breast cancer, gastric cancer, hepatocellular carcinoma, and non-Hodgkin lymphoma.</p>
      <p>Two phase III trials assessed the efficacy of everolimus on PFS. In the Radiant-3 trial [<xref ref-type="bibr" rid="B4">4</xref>] conducted on patients with pancreatic neuroendocrine tumours, everolimus was associated with a significant 6.4-month increase in median PFS versus placebo. Median PFS was 11&#xA0;months with everolimus plus best supportive care, compared with 4.6&#xA0;months for placebo plus best supportive care (hazard ratio&#x2009;=&#x2009;0.35; 95% Confidence Interval (CI) [0.27-0.45]). In the Radiant-2 trial [<xref ref-type="bibr" rid="B3">3</xref>], the improvement in PFS in patients with advanced neuroendocrine tumours just missed statistical significance at the predetermined level set by the study design, but median overall survival was higher in the everolimus arm compared with the placebo arm, 12 <italic>vs.</italic> 8.6&#xA0;months (hazard ratio&#x2009;=&#x2009;0.77, P&#x2009;=&#x2009;0.026), respectively.</p>
      <p>As described in the literature [<xref ref-type="bibr" rid="B5">5</xref>], the most frequently reported side-effects of everolimus include infections, oedematous syndrome, cutaneous reactions (<italic>e.g.,</italic> rash, itching, and dry skin), gastrointestinal problems (<italic>e.g.</italic>, mucositis, diarrhoea, anorexia, nausea, and vomiting), asthenia, acute renal insufficiency, and pulmonary disease, including pneumonitis as in the case of our patient. Non-infectious pneumonitis is a known class effect of rapamycin derivatives. This side-effect was found in 13.5% [<xref ref-type="bibr" rid="B5">5</xref>] to 25% [<xref ref-type="bibr" rid="B6">6</xref>] of cases in the two major everolimus efficacy trials (12% in the Radiant-2 trial and 17% in Radiant-3) and was more commonly Grade 1&#x2013;2 (10-14% being Grade 1&#x2013;2 and 2&#x2013;3% Grade 3&#x2013;4) [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>].</p>
      <p>Symptoms of pneumonitis include dry cough, dyspnoea, hypoxemia, asthenia, fever, and weight loss [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], developing between 34 and 491&#xA0;days after treatment initiation [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref>]. On radiographic and CT lung imaging, infiltration or opacity of the lower lobes may be observed [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B9">9</xref>], even in the absence of pulmonary symptoms [<xref ref-type="bibr" rid="B5">5</xref>]. The BAL shows lymphocytic alveolitis, with samples testing negative for infection [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. The development of this type of pneumonitis appears to be independent from serum everolimus levels [<xref ref-type="bibr" rid="B8">8</xref>]. The physiopathology of pneumonitis is likely based on the accumulation of collagen in the extracellular matrix, the proliferation and migration of fibroblasts, and the loss of functional alveolar gas exchange units [<xref ref-type="bibr" rid="B10">10</xref>].</p>
      <p>Management depends on the severity of clinical symptoms, though the pneumonitis is usually reversible after dose reduction or treatment discontinuation [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. In cases where the diagnosis is based on radiographic findings alone without any associated symptoms, everolimus may be continued at the same dose. In cases of moderate to severe symptoms, everolimus therapy should be temporarily stopped until pneumonitis has resolved, then re-instituted at a lower dose. Corticosteroids may also be administered [<xref ref-type="bibr" rid="B5">5</xref>].</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>These relatively frequent side effects of everolimus should be familiar to clinicians, including nonspecialists, and be monitored carefully to allow for prompt management. Recommendations for optimal management strategies are necessary.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Competing interest</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>Manuscript writing: L Dahan and C Sibertin-Blanc. Review: L Dahan, C Sibertin, JF Seitz. Final responsibility for the decision to submit for publication: L Dahan. All authors read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Missiaglia</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Dalai</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Barbi</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway</article-title>
          <source>J Clin Oncol</source>
          <year>2010</year>
          <volume>28</volume>
          <issue>2</issue>
          <fpage>245</fpage>
          <lpage>255</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2008.21.5988</pub-id>
          <pub-id pub-id-type="pmid">19917848</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Faivre</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Kroemer</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Raymond</surname>
            <given-names>E</given-names>
          </name>
          <article-title>Current development of mTOR inhibitors as anticancer agents</article-title>
          <source>Nat Rev Drug Disc</source>
          <year>2006</year>
          <volume>5</volume>
          <fpage>671</fpage>
          <lpage>688</lpage>
          <pub-id pub-id-type="doi">10.1038/nrd2062</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="other">
          <name>
            <surname>Pavel</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hainsworth</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Baudin</surname>
            <given-names>E</given-names>
          </name>
          <article-title>A randomized double blind, placebo-controlled multicenter phase III trial of everolimus plus octreotide LAR vs placebo plus Octreotide LAR in patients with advanced neuroendocrine tumors (Radiant-2)</article-title>
          <source>Eur J Cancer</source>
          <year>2010</year>
          <comment>LBA8</comment>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Yao</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Shah</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Ito</surname>
            <given-names>T</given-names>
          </name>
          <article-title>RAD001 In advanced neuroendocrine tumors, third trial (RADIANT-3) study group</article-title>
          <source>Everolimus for advanced pancreatic neuroendocrine tumors</source>
          <year>2011</year>
          <volume>364</volume>
          <issue>6</issue>
          <fpage>514</fpage>
          <lpage>523</lpage>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>White</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Camus</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Endo</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma</article-title>
          <source>Am J Respir Crit Care Med</source>
          <year>2010</year>
          <volume>182</volume>
          <issue>3</issue>
          <fpage>396</fpage>
          <lpage>403</lpage>
          <pub-id pub-id-type="doi">10.1164/rccm.200911-1720OC</pub-id>
          <pub-id pub-id-type="pmid">20194812</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>White</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>LH</given-names>
          </name>
          <name>
            <surname>Dimitrijevic</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001)</article-title>
          <source>J Thorac Oncol</source>
          <year>2009</year>
          <volume>4</volume>
          <issue>11</issue>
          <fpage>1357</fpage>
          <lpage>1363</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181ba20b1</pub-id>
          <pub-id pub-id-type="pmid">19745764</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Errasti</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Izquierdo</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Mart&#xED;n</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience</article-title>
          <source>Transplant Proc</source>
          <year>2010</year>
          <volume>42</volume>
          <issue>8</issue>
          <fpage>3053</fpage>
          <lpage>3054</lpage>
          <pub-id pub-id-type="doi">10.1016/j.transproceed.2010.07.066</pub-id>
          <pub-id pub-id-type="pmid">20970608</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rodr&#xED;guez-Moreno</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ridao</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Garc&#xED;a-Ledesma</surname>
            <given-names>P</given-names>
          </name>
          <article-title>Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center</article-title>
          <source>Transplant Proc</source>
          <year>2009</year>
          <volume>41</volume>
          <issue>6</issue>
          <fpage>2163</fpage>
          <lpage>2165</lpage>
          <pub-id pub-id-type="doi">10.1016/j.transproceed.2009.06.003</pub-id>
          <pub-id pub-id-type="pmid">19715862</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Otton</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hayward</surname>
            <given-names>CS</given-names>
          </name>
          <name>
            <surname>Keogh</surname>
            <given-names>AM</given-names>
          </name>
          <article-title>Everolimus-associated pneumonitis in 3 heart transplant recipients</article-title>
          <source>J Heart Lung Transplant</source>
          <year>2009</year>
          <volume>28</volume>
          <issue>1</issue>
          <fpage>104</fpage>
          <lpage>106</lpage>
          <pub-id pub-id-type="doi">10.1016/j.healun.2008.10.003</pub-id>
          <pub-id pub-id-type="pmid">19134540</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>S&#xE1;nchez-Fructuoso</surname>
            <given-names>AI</given-names>
          </name>
          <name>
            <surname>Ruiz</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>P&#xE9;rez-Flores</surname>
            <given-names>I</given-names>
          </name>
          <article-title>Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus</article-title>
          <source>Transplant Proc</source>
          <year>2010</year>
          <volume>42</volume>
          <issue>8</issue>
          <fpage>3050</fpage>
          <lpage>3052</lpage>
          <pub-id pub-id-type="doi">10.1016/j.transproceed.2010.07.083</pub-id>
          <pub-id pub-id-type="pmid">20970607</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Alexandru</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ortiz</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Baldovi</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Severe everolimus-associated pneumonitis in a renal transplant recipient</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2008</year>
          <volume>23</volume>
          <issue>10</issue>
          <fpage>3353</fpage>
          <lpage>3355</lpage>
          <pub-id pub-id-type="doi">10.1093/ndt/gfn401</pub-id>
          <pub-id pub-id-type="pmid">18658177</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Exp&#xF3;sito</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>de Prada</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>G&#xF3;mez-Rom&#xE1;n</surname>
            <given-names>JJ</given-names>
          </name>
          <article-title>Everolimus-related pulmonary toxicity in heart transplant recipients</article-title>
          <source>J Heart Lung Transplant</source>
          <year>2008</year>
          <volume>27</volume>
          <issue>7</issue>
          <fpage>797</fpage>
          <lpage>800</lpage>
          <pub-id pub-id-type="doi">10.1016/j.healun.2008.03.016</pub-id>
          <pub-id pub-id-type="pmid">18582812</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
